Application of syringaresinol in preparation of medicine for preventing and treating diabetic nephropathy

A technology for diabetic nephropathy and syringaresinol, which is applied in the fields of drug combination, urinary system diseases, food science, etc., can solve the problem that there is no syringaresinol for diabetic nephropathy, and achieves the expansion of new uses, improvement of kidney damage, and less toxic and side effects. Effect

Pending Publication Date:
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, there is no relevant report about syringaresin in the preparation of drugs for the prevention and treatment of diabetic nephropathy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of syringaresinol in preparation of medicine for preventing and treating diabetic nephropathy
  • Application of syringaresinol in preparation of medicine for preventing and treating diabetic nephropathy
  • Application of syringaresinol in preparation of medicine for preventing and treating diabetic nephropathy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Embodiment one: the detection of blood sugar, urine albumin and urine creatinine, appended figure 1 The test results of blood glucose, urine albumin and urine creatinine in mice are given.

[0021] Randomly divide 24 male C57BL / 6 mice aged 6-8 weeks into the control group (CON group, 8) and the model group (16); Inject STZ intraperitoneally; 1 week after STZ injection, cut off the tip of the tail of the mouse to collect blood from the tail vein to detect the blood glucose level of the mouse. If the blood glucose > 11.4mM, the diabetic mice were successfully modeled; the diabetic mice were randomly divided into the model group (DCM group, 8) and drug treatment group (DCM+SYR group, 8); the mice in the drug treatment group were treated by intragastric administration of 25 mg / kg dose of SYR for 8 weeks, and the mice in other groups were treated by intragastric administration of normal saline at the same dose as a control. And the blood glucose of mice in each group was de...

Embodiment 2

[0023] Example 2: Masson staining of kidney tissue

[0024] Soak the trimmed kidney tissue in 4% paraformaldehyde, fix at room temperature for more than 24 hours, perform gradient dehydration and embedding, and make 6 μm tissue sections; after dewaxing and rehydration, hematoxylin staining for 5-10 minutes; acidic ethanol differentiation 5-15s; the bluing solution turns blue for 3-5min; ponceau staining for 5-10min; dehydrated and transparent; figure 2 .

Embodiment 3

[0025] Example 3: Sirius Scarlet Staining of Kidney Tissue

[0026] Soak the trimmed kidney tissue in 4% paraformaldehyde, fix at room temperature for more than 24 hours, perform gradient dehydration and embedding, and make 6 μm tissue sections; after dewaxing and rehydration, stain with Sirius red staining solution for 1 hour; hematoxylin stains cell nuclei 8-10min; conventional dehydration and transparency; neutral gum sealing; observation and photography under a 400-fold microscope, see attached figure 2 .

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of syringaresinol in preparation of a medicine for preventing and treating diabetic nephropathy, and belongs to the technical field of application of syringaresinol. The syringaresinol has a structural formula as follows: the administration dosage of the syringaresinol is 25mg/kg, and the syringaresinol can be prepared into any one of various forms such as injection, tablets, powder, granules, capsules, oral liquid, ointment, cream, spray, aerosol and the like. The application of syringaresinol disclosed by the invention has the beneficial effects that the syringaresinol can remarkably improve kidney injury caused by diabetes without influencing blood sugar of diabetic mice, a new thought is provided for research and development of a new drug for diabetic nephropathy, and meanwhile, the new application of the syringaresinol is also expanded.

Description

technical field [0001] The invention relates to the application of syringaresin in the preparation of drugs for preventing and treating diabetic nephropathy, and belongs to the technical field of syringaresin application. Background technique [0002] Diabetic nephropathy (diabetic nephropathy, DN) is the main cause of end stage renal disease (end stage renal disease, ESRD) and the death of diabetic patients. Healthy global public health conundrum. DN is a microangiopathy caused by diabetes, which is clinically characterized by progressive renal impairment, accompanied by clinical manifestations such as proteinuria, edema, hypertension, and decreased glomerular filtration rate. Extracellular matrix (ECM) protein deposition, glomerular basement membrane thickening and charge barrier loss, glomerular mesangial matrix expansion, foot process fusion loss and podocyte loss are the main pathological features of DN. The pathogenesis of DN is extremely complex, and it is currently...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/34A61P3/10A61P13/12A23L33/105
CPCA61K31/34A61P3/10A61P13/12A23L33/105A23V2002/00A23V2200/328A23V2200/30A23V2250/2132
Inventor 杨亮栗广如漆智
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap